{"id":417,"date":"2024-05-08T08:00:00","date_gmt":"2024-05-08T12:00:00","guid":{"rendered":"https:\/\/www.techsequences.org\/podcasts\/?p=417"},"modified":"2024-05-06T18:57:30","modified_gmt":"2024-05-06T22:57:30","slug":"ai-human-ingenuity-the-best-equation-for-drug-discovery","status":"publish","type":"post","link":"https:\/\/www.techsequences.org\/podcasts\/2024\/05\/ai-human-ingenuity-the-best-equation-for-drug-discovery\/","title":{"rendered":"AI + Human Ingenuity: the best equation for drug discovery"},"content":{"rendered":"\n

Guest:<\/strong> Dave Hallett<\/p>\n\n\n\n

Cancer, called the \u201cEmperor of All Maladies\u201d has been a formidable adversary of mankind since time immemorial. With its multitude of forms and elusive nature, cancer presents a daunting challenge for drug discovery. However, AI offers a glimmer of hope. From lung and breast cancer to melanoma and leukemia, AI-driven drug discovery is harnessing the power of machine learning, deep learning, and predictive analytics, to target a diverse array of cancer types for more effective treatments. <\/p>\n\n\n\n

Join us for a conversation with Dr. Dave Hallet, an \u00a0experienced drug hunter with over 20 years\u2019 experience leading successful teams and collaborations for drug discovery. Dave is also the Chief Science Officer and the interim CEO at Exscientia, a publicly listed global drug discovery company headquartered in the UK.<\/p>\n\n\n\n

Hosted by:<\/strong> Alexa Raad and Leslie Daigle.<\/p>\n\n\n\n

Further reading:<\/strong><\/p>\n\n\n\n